Safety, Tolerability, and Effect of LY2405319 After Multiple Injections in Subjects With Type 2 Diabetes

Safety, Tolerability, PK and PD of LY2405319 After Multiple Subcutaneous Injections in Subjects With Type 2 Diabetes

This study intends to evaluate how safe and well tolerated the LY2405319 compound is when given to people for 7 days (in Part 1) and 28 days (in Part 2). This study intends to also determine if there is a positive effect on lowering the level of glucose in people with type 2 diabetes.

Subjects in Part 1 will be randomized to receive LY2405319 or placebo over 7 days in one of 4 dose level groups, in ascending order: 1 mg, 3 mg, 10 mg, or 20 mg.

Subjects in Part 2 will be randomized to receive LY2405319 or placebo over 28 days, and will receive the dose level determined to be the most well tolerated in Part 1.

Inclusion Criteria:

• Men and women without child bearing capability
• Ages 35 to 70 years
• Type 2 diabetic subjects, diagnosed for at least 3 months
• Average body weight (relative to height)
• Willing to be available for the duration of the study

Exclusion Criteria:

• Significant medical illnesses (except Type 2 diabetes)
• Abnormal 12-lead electrocardiogram (ECG )
• Current or previous use of insulin for greater than 7 days for control of diabetes
• Regular use of drugs of abuse
• Excessive alcohol use